Mitral Regurgitation Market

Mitral regurgitation (MR) is the backflow of blood from the left ventricle into the left atrium during left ventricular systole. The mitral valve is located in the opening between the left atrium and the left ventricle. It opens to allow blood from the left atrium to fill the left ventricle. When the left ventricle contracts, the mitral valve closes so that pumped blood can only flow into the aorta. When the mitral valve is not fully closed, some blood can leak back into the left atrium. Mitral regurgitation can be divided into primary and secondary MR according to the pathogenesis. Primary mitral regurgitation is due to the pathological changes of one or more of the mitral valve leaflets, valve annulus, chordae tendineae and papillary muscles, such as degenerative disease or rheumatic disease, which cause the mitral valve to fail to close normally. Secondary mitral valve regurgitation is functional mitral valve regurgitation, which is caused by the disease of the heart itself or the valve supporting structure, such as pathological changes of the myocardium leading to pathological dilatation of the left ventricle and mitral valve annulus or Mitral regurgitation due to localized displacement of the left ventricle and subvalvular device. The current quantitative assessment of mitral valve regurgitation, the current standards of various guidelines and documents are not completely consistent, generally divided into mild, moderate and severe, this classification is relatively broad, can not well reflect the changes and manifestations before and after surgery effect of surgery. In the MitraClip system clinical trial, mitral regurgitation was divided into no (0+), mild (1+), moderate (2+), moderate to severe (3+), severe (4+), and then more This classification method is used in several clinical studies of mitral valve regurgitation interventional therapy.

Mitral Regurgitation Market contains market size and forecasts of Mitral Regurgitation in Global, including the following market information:

• Global Mitral Regurgitation Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

• The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
• Primary Mitral Regurgitation Segment to Reach $ Million by 2028, with a % CAGR in next six years.
• The global key manufacturers of Mitral Regurgitation include Edwards Lifesciences, Abbott, CardioSolution, NeoChord, Mitralign, Medtronic, Boston Scientific, Mitralix and Shanghai Hanyu Medical Technology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
• We surveyed the Mitral Regurgitation companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

• Primary Mitral Regurgitation
• Secondary Mitral Regurgitation

• Transapical
• Via Stock and Via Interstitial
• Right Internal Jugular Vein

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

• Key companies Mitral Regurgitation revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Mitral Regurgitation revenues share in global market, 2021 (%)

• Edwards Lifesciences
• Abbott
• CardioSolution
• NeoChord
• Mitralign
• Medtronic
• Boston Scientific
• Mitralix
• Shanghai Hanyu Medical Technology
• Valgen Holding Corporation
• NeoChord
• CoreMedic
• Babic Chord
• Gore Medical
• Valtech Cardio
• Transcardiac
• ChoRe
• AVVIE
• Cardiovalve
• HighLife SAS
• Neovasc
• MitrAssist Lifesciences
• Shanghai NewMed Medical
• Peijia Medical
• MicroPort CardioFlow Medtech